Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GLI2 | P10070 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18466440 | 1.00 | FFAR3 (0.44) | FFAR3GLI1CYP3A4GLI2CCNT1 | |
| SCHEMBL3505753 | 0.84 | GLI1 (0.34) | FFAR3GLI1CYP3A4GLI2STAT3 | |
| SCHEMBL20446702 | 0.84 | GLI1 (0.34) | FFAR3GLI1CYP3A4GLI2STAT3 | |
| SCHEMBL29827658 | 0.79 | SMN1; SMN2 (0.35) | GLI1CYP3A4GLI2 | |
| SCHEMBL25905863 | 0.79 | SMN1; SMN2 (0.35) | GLI1CYP3A4GLI2 | |
| SCHEMBL10069349 | 0.79 | FFAR3 (0.42) | FFAR3HSD11B1MAPK1 | |
| SCHEMBL21181627 | 0.78 | FFAR3 (0.43) | FFAR3CCNT1CDK9 | |
| SCHEMBL13185545 | 0.77 | FFAR3 (0.41) | FFAR3CCNT1CDK9MAPK1 | |
| SCHEMBL11145508 | 0.77 | GLI1 (0.30) | GLI1CYP3A4GLI2 | |
| SCHEMBL16884655 | 0.76 | FFAR3 (0.40) | FFAR3CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0093840-B1 | PROCESS FOR THE PREPARATION OF KETONIC COMPOUNDS | FIRMENICH SA (CH) | 1985-05-22 | — | — | EP | claimed |
| JP-4226943-A | — | — | None | — | — | JP | disclosed |
| EP-2884976-B1 | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-07-24 | — | — | EP | disclosed |
| US-9487504-B2 | Imidazolyl analogs as syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487490-B2 | 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150191434-A1 | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2015-06-25 | — | — | US | disclosed |
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| EP-1914256-A1 | COMPOSITION, ACTINIC ENERGY RADIATION HARDENABLE COMPOSITION AND EPOXY COMPOUND | Konica Minolta Medical & Graphic, Inc. (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | disclosed |
| US-7244473-B2 | Active ray curable ink-jet composition, image forming method using the same, ink-jet recording apparatus, and triarylsulfonium salt compound | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20070054974-A1 | Active ray curable ink-jet composition, image forming method using the same, ink-jet recording apparatus, and triarylsulfonium salt compound | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060264529-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | KONICA MINOLTA HOLDINGS, INC. (JP) | 2006-11-23 | — | — | US | disclosed |
| US-20040244641-A1 | Active ray curable ink-jet composition, image forming method using the same, ink-jet recording apparatus, and triarylsulfonium salt compound | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040167315-A1 | Active energy ray curable composition | KONICA MINOLTA HOLDINGS, INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| JP-H04226943-A | (+)-(R)METHYL 1,4-DIMETHYL-3-CYCLOHEXENE-1-CARBOXYLATE, METHOD FOR IMPARTING AROMA CHARACTERISTIC TO PERFUME COMPOSITION AND CONSUMABLE MATERIAL AND ENHANCING OR REFORMING THE SAME AND PRODUCTION OF PERFUME COMPOSITION, CONSUMABLE MATERIAL AND NEW COMPOUND | FIRMENICH SA | 1992-08-17 | — | — | JP | disclosed |
| EP-0093840-B1 | PROCESS FOR THE PREPARATION OF KETONIC COMPOUNDS | FIRMENICH SA (CH) | 1985-05-22 | — | — | EP | disclosed |
| EP-0093840-A1 | Process for the preparation of ketonic compounds | FIRMENICH SA (CH) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | FFAR3 2223/4885GLI1 2351/4885CYP3A4 1069/4885 |
| US-20150191434-A1 | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | FFAR3 610/4885GLI1 108/4885CYP3A4 369/4885 |
| US-20150175575-A1 | IMIDAZOLYL ANALOGS AS SYK INHIBITORS | SYK, BTK, LCK | FFAR3 3313/4885GLI1 4407/4885CYP3A4 1425/4885 |
| US-20040244641-A1 | Active ray curable ink-jet composition, image forming method using the same, ink-jet recording apparatus, and triarylsulfonium salt compound | JAK1, INO80, ROR1 | FFAR3 3028/4885GLI1 97/4885CYP3A4 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.